{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 23 of 74', \"Any alterations in the patient's condition which justifies the discontinuation of\", \"treatment in the investigator's opinion\", 'No further clinical benefit expected', 'Patient misses more than 28 consecutive days of planned treatment (see section', '9.6.3)', 'With ongoing consent, patients should remain in the trial and be followed up according', 'to the protocol visit schedules.', '8.6.2', 'Withdrawal of consent', 'Patients may withdraw their consent to participate in the trial at any time. If the patient', 'explicitly states their wish not to contribute further data to the trial, the investigator', 'should inform the co-ordinating centre in writing and the withdrawal of consent should', \"be documented by the investigator in the patient's case report form (CRF). However,\", 'data and samples collected up to the time of consent withdrawal will be included in the', 'data reported for the trial.', '9', 'Trial Treatments', '9.1', 'General Principles', 'Patients in both arms of the trial should begin their allocated treatments within 7', 'days from the date of randomisation.', 'Safety assessments including haematology and biochemistry assessments are', 'required prior to Day 1 treatment of each cycle for the first year and every other', 'cycle thereafter. Safety assessments should also be performed, at the end of', 'protocol treatment (30 days from the date of last protocol treatment dose', 'administered); Details are provided in Section 10.2 and summarised in the', 'Schedule of Assessments in Section 10.7.', 'Dosage modifications are summarised in Section 9.6.', 'Specific details for the dabrafenib + trametinib regimen are given below. It is the', 'responsibility of the investigator to ensure that recommendations in the UK SmPCs for', 'administration of the dabrafenib and trametinib are followed. The SmPC is updated', 'from time to time, up-to-date UK SmPCs are posted on the Medicine Guides Website', 'http://www.medicines.org.uk.', '9.2 Investigational Medicinal products', 'For the purpose of this trial, dabrafenib and trametinib are both considered as', 'Investigational Medicinal Products (IMPs) conducted within a Clinical Trial Authorisation', '(CTA) under the Notification Scheme for Type A trials.', '9.2.1', 'Legal status of the drugs and Risk Categorisation.', 'The current regulatory framework in the UK/EU allows for a range of risk-adapted', 'approaches.', 'In this instance Dabrafenib and trametinib are both licensed for use in the UK for the', 'treatment of BRAFV600 mutant stage 3 unresectable and metastatic melanoma.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 24 of 74', 'Dabrafenib and trametinib are commercially available within the UK and are fully', 'commissioned standard treatments for advanced melanoma.', 'The INTERIM trial is designed to test intermittent scheduling of optimal MAPkinase', 'therapy in a BRAF mutant advanced melanoma population.', 'Clinical experience shows that intermittent dosing can successfully manage drug-', 'induced toxicity and sustain patients on BRAF targeted treatment. Intermittent dosing', 'can attenuate relief of upstream feedback within the MAPkinase pathway, a mechanism', 'known to contribute to drug resistance.', 'Using the risk-categorisation method, this trial has been categorised as Type A.', 'For further details of composition of either IMP, refer to the current version of the', \"manufacturer's Summary of Product Characteristics (SmPC) for the brand used, which\", 'can be accessed via the Electronic Medicines Compendium (eMC) website:', 'http://www.medicines.org.uk/emc. A reference copy of both SmPCs can be found in the', 'Investigator Site Files; please note however that these may not necessarily be the most', 'up-to-date versions.', '9.3', 'Treatment Summary', 'Patients will be randomised equally between the following arms and self administer', 'both dabrafenib and trametinib.', '9.3.1', 'Standard Arm: dabrafenib + trametinib standard arm (continuous', 'schedule)', 'Dabrafenib taken orally 150mg twice daily 12 hours apart, on days 1 - 28 of a 28 day', 'cycle', 'Trametinib taken orally 2mg once daily, on days 1 - 28 of a 28 day cycle', '9.3.2', 'Experimental Arm: dabrafenib + trametinib experimental arm', '(intermittent schedule)', 'Dabrafenib taken orally 150mg twice daily 12 hours apart, on days 1 - 21 of a 28 day', 'cycle', 'Trametinib taken orally 2mg once daily, on days 1 - 14 of a 28 day cycle', '9.3.3', 'Duration of treatment', 'Patients will continue on allocated treatment as long as they benefit from the treatment', 'and it is tolerable (see section 8.6.1 for full protocol treatment withdrawal criteria)', '9.3.4', 'Drug administration', 'Dabrafenib', 'Dabrafenib capsules are to be swallowed whole with water. The capsules should not be', 'chewed or opened and should not be mixed with food or liquids due to chemical', 'instability of dabrafenib. Dabrafenib should be taken at least one hour before, or at', 'least 2 hours after a meal.', 'It is recommended that the doses of dabrafenib are taken at similar times every day,', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}